[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
July 2015

Restricting Benzodiazepines to Short-Term Prescription

Author Affiliations
  • 1Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
  • 2Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut
  • 3Clinical Neuroscience Division, VA National Center for Posttraumatic Stress Disorder, VA Connecticut Healthcare System, West Haven
  • 4Yale–New Haven Hospital, New Haven, Connecticut
  • 5The Atlantic, Washington, DC
  • 6Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina
  • 7Duke Clinical Research Institute, Durham, North Carolina
JAMA Psychiatry. 2015;72(7):734-735. doi:10.1001/jamapsychiatry.2015.0351

To the Editor In their Editorial, Moore et al1 presented as a foregone conclusion, unsupported by reference to the published literature, that benzodiazepines rapidly lose their efficacy as hypnotics and anxiolytics, while being associated with growing risks over time. From this perspective, long-term prescription of these drugs would seem to be unethical.

First Page Preview View Large
First page PDF preview
First page PDF preview
×